

PTO/SB/21 (09-04)

Approved for use through 07/31/2006 OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL
FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission


Application Number	10/644,411
Filing Date	August 20, 2003
First Named Inventor	Jean-François RIOU et al.
Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	ST01004 US CIP

RECEIVED
CENTRAL FAX
CENTER
NOV 04
2005

ENCLOSURES (Check all that apply)


<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> <input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input checked="" type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/>
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	<input type="checkbox"/>
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/>
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	<input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/>
<input type="checkbox"/> <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		<input type="checkbox"/>
Remarks		
1. Transmittal Letter - (1 page)		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	AVENTS PHARMACEUTICALS INC.		
Signature			
Printed name	Paul R. Darkes		
Date	November 04, 2005	Reg. No.	33,862

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. (USPTO FAX NO. 571-273-8300; Total No. of Pages Transmitted: 2)

Signature 

Typed or printed name Jonas Pierre, Sr.

Date November 04, 2005


This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re Application of
RIOU et al.

Application No.: 10/644,411

Filed: August 20, 2003

Title: OXINDOLES WHICH ARE INHIBITORS
OF CDK-1 AND THEIR APPLICATION IN
THERAPEUTICSExaminer: Not Yet Known
Art Unit: Not Yet KnownRECEIVED
CENTRAL FAX CENTER
NOV 04 2005

Certificate of Mailing or Transmission	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO, on the date indicated below.	
Date of Deposit: November 4, 2005	
Printed Name of Person Signing Certificate: <u>Janina Pierce, Sr.</u>	
Signature: 	

STATUS INQUIRYCommissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

The Applicants request a Status Inquiry for Application Serial No. 10/644,411, filed August 20, 2003.

The Commissioner is hereby authorized to charge any fees which may be required by this paper, or credit any overpayment, to Deposit Account No. 18-1982.

Respectfully submitted,


 Paul R. Darkes, Reg. No., 33,862
 Attorney/Agent for Applicant
Aventis Pharmaceuticals Inc.
(a member of the sanofi-aventis group)
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (610) 889-8458
Telefax (908) 231-2626

Aventis Docket No. ST01004 US CIP